SAN DIEGO, and TOKYO, April 14, 2020 – MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today jointly announced that the companies have entered into a global license, development and commercialization agreement to further develop and commercialize MEI’s ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta (PI3Kδ), in clinical development for …
First Approved Treatment for XLH in Canada that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease.
Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency’s (EMA) scientific committee, has adopted a Positive Opinion recommending approval of the marketing authorisation of mogamulizumab
The positive recommendation marks a step change in the management of XLH for children and young people, and the first significant clinical advancement for the condition in the last 35 years.
Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for Poteligeo®
Ultragenyx & KKI today announced that the FDA has approved Crysvita® for the treatment of XLH in adult and paediatric patients one year of age and older.
KKI & Ultragenyx Pharmaceutical announce that Crysvita received a positive European Commission decision granting a conditional marketing authorisation
Ultragenyx & Kyowa Kirin announce Burosumab receives positive CHMP opinion for the treatment of X-Linked…
Kyowa Kirin International PLC, a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) today announces Germany’s Federal Institute for…
Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), hosted Dr. Nobuo Hanai, President and Chief Executive Officer of KKI’s parent company, Kyowa Hakko Kirin Co. Ltd., at the company’s head office in Galashiels this week.
Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), announces that it is to expand its headquarters facility in Galashiels, Scotland, to accommodate the growth of the business. The news comes as KKI reports record turnover of £251m for 2016, growth of 13% over 2015 revenues of £222m. KKI (formerly known as ProStrakan) is a wholly-owned subsidiary of Japan-based Kyowa …
- Page 1 of 2